Peng Y - Search Results

1

[Corrigendum] HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.

Zong B, Sun L, Peng Y, Wang Y, Yu Y, Lei J, Zhang Y, Guo S, Li K, Liu S. Zong B, et al. Among authors: peng y. Oncol Rep. 2021 Sep;46(3):195. doi: 10.3892/or.2021.8146. Epub 2021 Jul 23. Oncol Rep. 2021. PMID: 34296290 Free PMC article.

2

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.

Zong B, Sun L, Peng Y, Wang Y, Yu Y, Lei J, Zhang Y, Guo S, Li K, Liu S. Zong B, et al. Among authors: peng y. Oncol Rep. 2021 Jul;46(1):138. doi: 10.3892/or.2021.8089. Epub 2021 May 26. Oncol Rep. 2021. PMID: 34036395 Free PMC article.

3

A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma.

Peng Y, Yu H, Zhang Y, Qu F, Tang Z, Qu C, Tian J, Zong B, Wang Y, Ren H, Liu S. Peng Y, et al. Sci Rep. 2021 Sep 2;11(1):17610. doi: 10.1038/s41598-021-97102-z. Sci Rep. 2021. PMID: 34475496 Free PMC article.

4

Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.

Xu Y, Peng Y, Shen M, Liu L, Lei J, Gao S, Wang Y, Lan A, Li H, Liu S. Xu Y, et al. Among authors: peng y. J Oncol. 2022 Apr 20;2022:1525245. doi: 10.1155/2022/1525245. eCollection 2022. J Oncol. 2022. PMID: 35498539 Free PMC article.

5

Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.

Zhang Y, Tian J, Qu C, Peng Y, Lei J, Li K, Zong B, Sun L, Liu S. Zhang Y, et al. Among authors: peng y. Breast Cancer. 2021 Jul;28(4):859-873. doi: 10.1007/s12282-021-01221-4. Epub 2021 Feb 10. Breast Cancer. 2021. PMID: 33569740 Free PMC article.

6

JAM2 predicts a good prognosis and inhibits invasion and migration by suppressing EMT pathway in breast cancer.

Peng Y, Li H, Fu Y, Guo S, Qu C, Zhang Y, Zong B, Liu S. Peng Y, et al. Int Immunopharmacol. 2022 Feb;103:108430. doi: 10.1016/j.intimp.2021.108430. Epub 2021 Dec 17. Int Immunopharmacol. 2022. PMID: 34923424

7

Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients.

Peng Y, Chen R, Qu F, Ye Y, Fu Y, Tang Z, Wang Y, Zong B, Yu H, Luo F, Liu S. Peng Y, et al. Cancer Biol Ther. 2020;21(2):189-196. doi: 10.1080/15384047.2019.1680057. Epub 2019 Nov 4. Cancer Biol Ther. 2020. PMID: 31684807 Free PMC article.

8

Assessment of the Predictive Role of Serum Lipid Profiles in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Qu F, Chen R, Peng Y, Ye Y, Tang Z, Wang Y, Zong B, Yu H, Liu S. Qu F, et al. Among authors: peng y. J Breast Cancer. 2020 Jun;23(3):246-258. doi: 10.4048/jbc.2020.23.e32. J Breast Cancer. 2020. PMID: 32595987 Free PMC article.

9

A look into the link between centrosome amplification and breast cancer.

Zhang Y, Tian J, Qu C, Peng Y, Lei J, Sun L, Zong B, Liu S. Zhang Y, et al. Among authors: peng y. Biomed Pharmacother. 2020 Dec;132:110924. doi: 10.1016/j.biopha.2020.110924. Epub 2020 Oct 28. Biomed Pharmacother. 2020. PMID: 33128942 Free article. Review.

10

Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer.

Peng Y, Yu H, Jin Y, Qu F, Ren H, Tang Z, Zhang Y, Qu C, Zong B, Liu S. Peng Y, et al. Front Immunol. 2021 Apr 27;12:666137. doi: 10.3389/fimmu.2021.666137. eCollection 2021. Front Immunol. 2021. PMID: 33986754 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20,166 results

Search Page

Filters